UCSF Helen Diller Family Comprehensive Cancer Center
Welcome,         Profile    Billing    Logout  
 428 Trials 
455 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kelly, Karen
NCT05947084: Comparison of Growth and Tolerance of Healthy Term Infants Fed Iron-Fortified Infant Formulas

Active, not recruiting
3
440
US
Infant Formula
Aussie Bubs, Inc.
Infant Development
04/25
04/25
NCT05412030: A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

Active, not recruiting
2
472
US
AFX3772, Prevnar 13, PCV13, Prevnar 20, PCV20
GlaxoSmithKline, Affinivax, Inc.
Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
07/26
07/26
NCT03474497: UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Recruiting
1/2
45
US
IL-2, Pembrolizumab, Radiotherapy, Radiation Therapy
Megan Daly, MD, Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
12/23
12/23
NCT02599454: Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Active, not recruiting
1
20
US
Atezolizumab, MPDL3280A, Stereotactic Body Radiation Therapy, SBRT
Megan Daly, MD, Genentech, Inc.
Stage I Non-Small Cell Lung Cancer
01/20
12/23
Chang, Susan M
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
NCT04540107: Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

Recruiting
1
300
US
Hyperpolarized Carbon C 13 Pyruvate, Hyperpolarized 13C-Pyruvate, Hyperpolarized Pyruvate (13C), Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging, 1H- Nuclear Magnetic Resonance Spectroscopic Imaging, 1H-nuclear magnetic resonance spectroscopic imaging, Magnetic Resonance Spectroscopy, MRS, MRS Imaging, MRSI, Proton Magnetic Resonance Spectroscopic Imaging
Susan Chang, GE Healthcare, Sigma-Aldrich, Phillips-Medisize, National Cancer Institute (NCI)
Recurrent World Health Organization (WHO) Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
01/27
01/27
Rugo, Hope
ARTEST, NCT04869943 / 2021-002176-39: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Terminated
3
52
Europe, US, RoW
Enobosarm, VERU-024, Exemestane, Mestane
Veru Inc.
Metastatic Breast Cancer
01/24
01/24
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
NCT03562637 / 2018-001438-16: Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Recruiting
3
668
Europe, US, RoW
adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment
OBI Pharma, Inc, OBI Pharma, Inc.
Triple Negative Breast Cancer
12/25
12/27
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
FOENIX-MBC2 TAS-120-201, NCT04024436 / 2019-001164-30: A Study of TAS-120 in Patients With Metastatic Breast Cancer

Completed
2
168
Europe, Canada, US
Futibatinib, TAS-120, Futibatinib plus Fulvestrant
Taiho Oncology, Inc., Taiho Pharma Europe Limited, TAIHO ONCOLOGY INC.
Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification
05/23
10/24
AVIATOR, NCT03414658: The Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Hourglass Mar 2019 - Dec 2019 : From trial for cancer (unspecified)
Active, not recruiting
2
100
US
Vinorelbine, Trastuzumab, Avelumab, Utomilumab
Adrienne G. Waks, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University
Breast Cancer
05/23
05/25
ASPRIA, NCT04434040: Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC

Active, not recruiting
2
40
US
Atezolizumab, Tecentriq, Sacituzumab govitecan, Trodelvy, IMMU-132
Dana-Farber Cancer Institute, Genentech, Inc., Stand Up To Cancer
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
12/25
12/27
NCT03990896: Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Recruiting
2
30
US
Talazoparib, Talzenna
Massachusetts General Hospital, Pfizer
Breast Cancer
07/25
12/25
NCT05079360: Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Withdrawn
2
200
US
Sabizabulin, Veru-111, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator, exemestane
Veru Inc.
Metastatic Breast Cancer
03/24
05/24
InCITe, NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting
2
150
US
Anti-OX40 Antibody PF-04518600, PF-04518600, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Binimetinib, ARRY-162, ARRY-438162, MEK162, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566, Liposomal Doxorubicin, Caelyx, Lipodox, Sacituzumab Govitecan, Trodelvy, Sacituzumab Govitecan-hziy
Hope Rugo, MD, Translational Breast Cancer Research Consortium, Hoosier Cancer Research Network, Array BioPharma, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University, Gilead Sciences
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
06/25
06/25
TBCRC 044, NCT03095352: Pembrolizumab with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease

Completed
2
70
US
Pembrolizumab, Carboplatin, Ribocarbo, Trastuzumab
Hope Rugo, MD, Mayo Clinic, Johns Hopkins University, Translational Breast Cancer Research Consortium, Massachusetts General Hospital, Merck Sharp & Dohme LLC
Breast Cancer, Chest Wall Disease
11/24
11/24
ATEMPT 2.0, NCT04893109: Adjuvant T-DM1 Vs TH

Recruiting
2
500
US
trastuzumab-emtansine, T-DM1, Kadcyla, Trastuzumab SC, Herceptin Hylecta, Paclitaxel, Taxol, Onxal
Dana-Farber Cancer Institute, Genentech, Inc.
Breast Cancer, HER2-positive Breast Cancer
05/25
05/28
Cornerstone001, NCT05163223: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

Terminated
2
10
US, RoW
AST-301(pNGVL3-hICD), AST-301, rhuGM-CSF, Leukine, Sargramostim, Placebo, Normal Saline, Pembrolizumab, Keytruda, Capecitabine, Xeloda
Aston Sci. Inc.
Breast Cancer
05/24
05/24
TBCRC 058, NCT06099769: A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Recruiting
2
201
US
Enzalutamide, Mifepristone, TPC
Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc., Breast Cancer Research Foundation, Corcept Therapeutics
Metastatic Breast Cancer
10/27
10/27
ENCORE, NCT06774027: Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Not yet recruiting
N/A
100
US
Specimen collection, Biospecimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Non-Investigational ADC, Medical Record Review, Medical Chart Review
University of California, San Francisco, Translational Breast Cancer Research Consortium, Gilead Sciences, Johns Hopkins University
HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Metastatic Breast Cancer, HR+ HER2 Breast Cancer, Metastatic Triple Negative Breast Cancers, Metastatic Triple-Negative Breast Carcinoma
12/30
12/30
Esserman, Laura J
NCT02872025: Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)

Active, not recruiting
1
42
US
Pembrolizumab, Keytruda, MK-3475, Intralesional mRNA 2752, mRNA 2752
Laura Esserman, Merck Sharp & Dohme LLC, ModernaTX, Inc.
Carcinoma, Intraductal, Noninfiltrating
03/26
03/26
WISDOM, NCT02620852: Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

Recruiting
N/A
100000
US
Complete a health questionnaire, Provide a saliva sample for genetic testing, Screening advice based on a comprehensive risk assessment, Screening advice based on a basic risk assessment
University of California, San Francisco, Patient-Centered Outcomes Research Institute, Robert Wood Johnson Foundation, Color Genomics, Inc., Salesforce, National Cancer Institute (NCI), Safeway Foundation, United States Department of Defense
Breast Cancer Screening, Breast Carcinoma in Situ, Breast Cancer
09/25
09/25
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Palefsky, Joel
ANCHOR, NCT02135419: Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

Completed
3
4446
US
imiquimod, Aldara, IMQ, R 837, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, Efudex, infrared photocoagulation therapy, infrared coagulation, IRC, thermal ablation therapy, laser therapy, therapy, laser, clinical observation, observation, laboratory biomarker analysis
AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas, University of California, San Francisco, University of Arizona
Anal Cancer, High-grade Squamous Intraepithelial Lesion, HIV Infection, Human Papilloma Virus Infection
08/21
03/24
NCT02059499: Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions

Active, not recruiting
3
91
US
imiquimod, Aldara, IMQ, R 837, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, questionnaire administration, laboratory biomarker analysis
AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas
Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion, HIV Infection
12/23
04/25
anal HSIL HIV-, NCT05555862: Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL

Active, not recruiting
2
17
US
Artesunate, Artesunic acid, dihydroartemisinin (DHA), artemisinin, Placebo
Frantz Viral Therapeutics, LLC, Amarex CRO, University of California, San Francisco, Anal Dysplasia Clinic MidWest, Laser Surgery Care
Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition, AIN 2/3, HPV Infection, Anal Dysplasia, HPV Disease
12/24
12/24
Rosenberg, Jonathan
COMPASS-CD, NCT04809363: A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Active, not recruiting
4
200
US
CDPATH™, PROSPECT, Blood Draw
Takeda
Crohn's Disease
10/25
06/26
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting
4
150
Canada, US
Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara
Takeda
Crohn's Disease
06/27
06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Recruiting
4
65
Canada, US
Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550
Takeda
Ulcerative Colitis
07/27
07/27
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
BAYOU, NCT03459846 / 2017-004556-27: A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer

Checkmark From BAYOU trial in combination with Imfinzi for urothelial cancer at ASCO-GU 2022
Feb 2022 - Feb 2022: From BAYOU trial in combination with Imfinzi for urothelial cancer at ASCO-GU 2022
Active, not recruiting
2
154
Europe, Canada, US, RoW
Durvalumab, Olaparib, Placebo
AstraZeneca
Urinary Bladder Neoplasms
10/20
12/24
EV-ECLIPSE, NCT05239624: Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Recruiting
2
23
US
Enfortumab vedotin, Pembrolizumab
Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc., Seagen Inc., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
06/26
NCT05868265: A Study of Enfortumab Vedotin in People with Urothelial Carcinoma of the Upper Urinary Tract

Recruiting
2
24
US
Enfortumab Vedotin, Radical surgery
Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc.
Urothelial Carcinoma
05/25
05/25
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
NCT05585879: Demonstrating Effective Salvage of Inadequate Colonoscopies

Terminated
N/A
16
US
Pure-Vu EVS
Motus GI Medical Technologies Ltd
Colorectal Screening
04/24
04/24
Munster, Pamela N
RENAVIV, NCT03592472 / 2018-001495-38: A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Recruiting
3
413
Europe, US, RoW
Pazopanib, Votrient®, Abexinostat, PCI-24781, Placebo
Xynomic Pharmaceuticals, Inc.
Renal Cell Carcinoma
12/24
06/25
NCT04190056: Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

Terminated
2
1
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Tamoxifen, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
University of California, San Francisco, Merck Sharp & Dohme LLC
Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
06/23
06/23
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Completed
1/2
169
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
11/24
12/24
ATLAS-101, NCT04503265: A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Recruiting
1/2
122
US
AMXI-5001:Dose Escalation Phase I, Phase I, Dose Escalation, AMXI-5001:Dose Expansion Phase II, Phase II, Dose Expansion
AtlasMedx, Incorporated
Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Prostate Cancer, Pancreatic Cancer
08/26
10/26
NCT06077877: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Recruiting
1/2
135
Canada, US
GSK4524101, Niraparib
GlaxoSmithKline
Neoplasms
12/27
11/29
DF1001-001, NCT04143711 / 2019-004706-10: Study of DF1001 in Patients With Advanced Solid Tumors

Recruiting
1/2
378
Europe, US
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Dragonfly Therapeutics, Dragonfly Therapeutics, Inc.
Solid Tumor, Adult
10/26
12/26
Biolen-PC, NCT04284761: A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

Completed
1
17
US, RoW
Bicalutamide implant
Alessa Therapeutics Inc.
Prostate Adenocarcinoma, Lower Urinary Tract Symptoms
05/23
05/23
NCT04257110: A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Active, not recruiting
1
208
US, RoW
BB-1701
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Locally Advanced/Metastatic HER2 Positive Solid Tumors
08/24
12/24
NCT04418167: JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Suspended
1
71
US
JSI-1187, Dabrafenib, TAFINLAR
JS InnoPharm, LLC
Solid Tumors
06/24
12/24
NCT04678648: A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Recruiting
1
134
US
RSC-1255 Dose Escalation, Phase 1a, Dose Escalation, RSC-1255 Dose Expansion, Phase 1b, Dose Expansion
RasCal Therapeutics, Inc.
Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
07/25
09/25
NCT01543763: Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ASCO 2014
More
Active, not recruiting
1
90
US
PZP115891, PCI-24781, abexinostat, S 78454, GW786034, Votrient™, Pazopanib
Pamela Munster, Pharmacyclics LLC., Novartis, Xynomic Pharmaceuticals, Inc., GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease
Metastatic Solid Tumors
01/24
12/24
NCT04774952: Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Active, not recruiting
1
108
US
RMC-5552
Revolution Medicines, Inc.
Solid Tumors
03/24
03/24
SGNSTNV-001, NCT04665921: A Study of SGN-STNV in Advanced Solid Tumors

Terminated
1
111
Europe, Canada, US
SGN-STNV
Seagen Inc.
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
03/24
03/24
NCT05838768: Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Recruiting
1
327
Europe, Japan, US, RoW
HRO761, pembrolizumab, irinotecan
Novartis Pharmaceuticals
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
05/29
05/29
NCT05277051: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Recruiting
1
141
Europe, Canada, Japan, US, RoW
GSK4381562, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
GlaxoSmithKline
Neoplasms
09/28
09/28
NCT05694715: Combination Therapy in Cancers With Mutations in DNA Repair Genes

Recruiting
1
24
US
Niraparib, Zejula, Small molecule inhibitor, Irinotecan, Camptosar, Irinotecan hydrochloride, CPT-11
University of California, San Francisco, GlaxoSmithKline
Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation, ATM Gene Mutation, PALB2 Gene Mutation
01/28
01/28
Rubenstein, James L
NCT05351593: Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

Recruiting
1/2
35
US
Tafasitamab, MOR208, Lenalidomide, Revlimid
James Rubenstein, Incyte Corporation
CNS Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
09/25
06/26
Ko, Andrew
RESET-RA, NCT04539964: Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

Active, not recruiting
3
243
US
Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation
SetPoint Medical Corporation
Rheumatoid Arthritis
05/24
10/27
NCT05221320: Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

Terminated
2
47
US
Ulixertinib, BVD-523, BVD523, Hydroxychloroquine
BioMed Valley Discoveries, Inc
Tumor, Solid, Gastrointestinal Cancer
05/24
07/24
DisTinGuish, NCT04363801: A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Hourglass Oct 2023 - Mar 2024 : Q4'23/Q1'24 - Initial ORR data from DisTinGuish trial for 2L gastric cancer
Oct 2023 - Dec 2023: Initial data from part C of DisTinGuish trial in combination with tislelizumab for 1L gastric cancer
Checkmark Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Nov 2022 - Nov 2022: Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Checkmark ORR, PFS and OS data from DisTinGuish trial in combination with tislelizumab for gastroesophageal junction cancer or gastric cancer
More
Active, not recruiting
2
232
Europe, US, RoW
DKN-01 300mg, DKN-01 600mg, DKN-01 400mg, Tislelizumab 200mg, Tislelizumab 400mg, Oxaliplatin, Capecitabine 1000mg/ m2 BID, Xeloda, Leucovorin Calcium, Folinic acid, Fluorouracil
Leap Therapeutics, Inc., BeiGene
Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
06/25
12/25
NCT05249101: A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

Recruiting
1/2
70
US
Ivaltinostat, Capecitabine, Xeloda
CG Pharmaceuticals, Inc
Metastatic Pancreatic Adenocarcinoma
02/26
06/26
RAMP205, NCT05669482: Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

Recruiting
1/2
40
US
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel, Gemzar, Abraxane
Verastem, Inc.
KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas
05/25
12/25
THREAD, NCT03825289: Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

Recruiting
1
39
US
Hydroxychloroquine, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
University of Utah, Novartis Pharmaceuticals
Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unresectable Pancreatic Carcinoma
01/25
01/26
Daud, Adil
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers

Active, not recruiting
2
77
Europe, Canada, US
SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Carcinoma, Non-Small- Cell Lung
01/24
10/25
NCT05060003: Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Terminated
2
7
US
Atezolizumab, Tecentriq, Tiragolumab, Signatera Assay
Washington University School of Medicine, Genentech, Inc.
Stage II Melanoma
11/23
11/23
OMNIA-1, NCT05578872 / 2021-006711-29: A Study of ANV419 Alone or in Combination with Approved Treatment in Patients with Cutaneous Melanoma ().

Completed
1/2
29
Europe, US
ANV419, Pembrolizumab, Ipilimumab
Anaveon AG, Anaveon AG
Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma
08/24
08/24
SGNBB228-001, NCT05571839: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Recruiting
1
275
Europe, Canada, US
PF-08046049
Seagen Inc.
Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
11/26
11/27
NCT05695898: XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy

Active, not recruiting
1
6
US
XmAb22841, CTLA-4 X LAG3, Bavunalimab, XmAb23104, PD1 X ICOS, XmAb104
University of California, San Francisco, Xencor, Inc.
Metastatic Melanoma, Advanced Melanoma
12/25
12/25
NCT05105100: Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

Recruiting
N/A
25
US
Biopsy, Excisional Biopsy, Biospecimen Collection, Specimen Collection
University of California, San Francisco, Merck Sharp & Dohme LLC
Melanoma, Advanced Melanoma
08/26
08/26
Chen, Lee-may
ZN-c3-004, NCT04814108: A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Recruiting
2
76
Canada, US, RoW
ZN-c3, azenosertib, KP-2638
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Uterine Serous Carcinoma
11/24
05/25
GOG-3026, NCT03673124: Ribociclib and Letrozole Treatment in Ovarian Cancer

Active, not recruiting
2
51
US
Ribociclib, Letrozole
Gynecologic Oncology Group, Novartis
Low Grade Serous Carcinoma
12/23
12/24
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
Martin, Thomas G
CFT7455-1101, NCT04756726: Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Recruiting
1/2
224
US
cemsidomide, CFT7455, Dexamethasone Oral
C4 Therapeutics, Inc.
Multiple Myeloma, Lymphoma, Non-Hodgkin's
09/25
12/25
NCT06348108: Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Not yet recruiting
1
38
US
Talquetamab, Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564, DuoBody Antibody JNJ-64407564, Iberdomide, CELMoD, CC-220, 1323403-33-3, Dexamethasone, Decadron, DexPak, Hemady, Bone Marrow Biopsy, Biopsy
Thomas Martin, MD, Bristol-Myers Squibb, Janssen Research & Development, LLC
Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
06/26
06/28
NCT02332850: Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

Active, not recruiting
1
83
Canada, US
Isatuximab, SAR 650984, Carfilzomib, Kyprolis, PR-171, Dexamethasone, Orgadrone, Spersadex, Visumetazone
Thomas Martin, MD, Amgen, Sanofi
Multiple Myeloma
12/24
12/24
NCT05577000: Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

Active, not recruiting
1
5
US
Manufactured Anti-BCMA CAR-T cells, Anti-BCMA CAR-T cells, Fludarabine, Fludara, Cyclophosphamide, Cytoxan
Thomas Martin, MD, Actavis Inc., University of California, Davis, Eugia Pharma Specialities Limited
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
10/28
10/43
NCT04640584: C-Brace Prospective Registry

Recruiting
N/A
250
Europe, US, RoW
C-Brace, Microprocessor-controlled Stance and Swing Orthosis (MP-SSCO)
Otto Bock Healthcare Products GmbH
Pareses, Lower Extremity
04/26
04/26
Fong, Lawrence
NCI-2017-01387, NCT02451423: Neoadjuvant Atezolizumab in Localized Bladder Cancer

Completed
2
23
US
Atezolizumab, MPDL3280A
Lawrence Fong, Genentech, Inc., The Bladder Cancer Advocacy Network, Conquer Cancer Foundation, National Cancer Institute (NCI), The V Foundation
Carcinoma, Transitional Cell
03/23
03/23
NCT03248570: Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

Completed
2
26
US
Pembrolizumab, KEYTRUDA, MK-3475, Chemotherapy
University of California, San Francisco, Merck Sharp & Dohme LLC, National Cancer Institute (NCI)
Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer
09/23
09/23
NCT04064190: Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Withdrawn
2
48
US
Vactosertib(TEW-7197)/ Durvalumab
MedPacto, Inc., AstraZeneca
Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma
12/23
12/24
NCT03007732: Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Active, not recruiting
2
23
US
Pembrolizumab, MK-3475, Keytruda, SD-101, Toll-like receptor 9, Leuprolide acetate, Intermittent androgen deprivation therapy, Abiraterone Acetate, Prednisone, Stereotactic Body Radiation Therapy, SBRT
David Oh, Prostate Cancer Foundation, Merck Sharp & Dohme LLC, TriSalus Life Sciences, Inc.
Prostatic Neoplasms
08/25
08/25
NCT03821246: Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Recruiting
2
68
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Tocilizumab, Actemra, Etrumadenant, AB928
David Oh, Genentech, Inc.
Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer
02/25
02/25
NCT05018273: Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

Completed
1
26
Europe, US
VB10.NEO, Atezolizumab, Tecentriq
Nykode Therapeutics ASA, Genentech, Inc., Vaccibody AS
Solid Tumors, Adult
10/24
10/24
Ryan, Charles
ARACOG, NCT04335682: Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

Recruiting
2
132
US
Darolutamide, Nubeqa, Enzalutamide, Xtandi
Alliance Foundation Trials, LLC., Bayer
Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer, Castrate Resistant Prostate Cancer, Hormone Sensitive Prostate Cancer, Non-metastatic Prostate Cancer
10/25
08/26
Kim, Won Seog
NCT01937806: Phase 3 and Extensional Study of Besifovir

Active, not recruiting
3
197
RoW
besifovir 150mg, tenofovir 300mg
IlDong Pharmaceutical Co Ltd
Chronic Hepatitis B
02/16
01/23
NCT05450601: A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients

Completed
3
249
RoW
HCP2102-1, HPP2104-1, HCP2102-2, HPP2104-2, RLD2106-1, HPP2103-1, RLD2106-2, HPP2103-2
Hanmi Pharmaceutical Company Limited
Hypertension
12/23
12/23
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen Inc.
Diffuse Large B-cell Lymphoma
05/25
04/27
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
B-Well1, NCT05630807 / 2021-005139-22: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

Active, not recruiting
3
941
Europe, Canada, Japan, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Chronic Hepatitis B, Hepatitis B, Chronic
11/25
05/26
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
NCT05067634 / 2020-005344-27: Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age with Partial-onset (focal) Seizures

Recruiting
3
140
Europe, US, RoW
Xcopri
SK Life Science, Inc.
Partial Epilepsy
05/26
07/26
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
REDIRECT, NCT04101331 / 2019-001003-20: Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

Completed
2
108
Europe, US, RoW
AFM13
Affimed GmbH
Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides
05/22
01/24
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL

Completed
2
171
US, RoW
AZD4205
Dizal Pharmaceuticals
Relapsed or Refractory Peripheral T Cell Lymphoma
10/23
02/24
DISTINKT, NCT04414163: A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Active, not recruiting
2
23
RoW
IMC-001, Not confirm yet
ImmuneOncia Therapeutics Inc.
Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma
07/24
02/26
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease

Not yet recruiting
2
393
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline
Liver Diseases, Alcoholic
12/26
03/27
Lemon-C, NCT04627753: Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.

Recruiting
2
30
RoW
Rituximab, lenalidomide, Truxima Inj, Lenalid
Kim, Seok Jin, Celltrion, Samyang Biopharmaceuticals Corporation
Primary CNS Lymphoma
11/25
11/26
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Recruiting
2
280
Europe, Canada, Japan, US, RoW
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
GlaxoSmithKline
Chronic Hepatitis B Virus Infection, Hepatitis B
10/27
10/27
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
07/27
 

Download Options